GAIN THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 7Avg age 61Avg tenure 4.8y
GM
Gene Mack
Chief Executive Officer
Age 52Since 2024-06-24Profile →
+11
Executives5
GM
Gene Mack→
Chief Executive Officer
Age 52Since 2024-06-24
GF
Gianluca Fuggetta→
Director of Finance/CFO
Age 37Since 2025-01-05
JH
Jonas Hannestad→
Chief Tech/Sci/R&D Officer
—Since 2024-03-24
JT
Joanne Taylor→
Chief Tech/Sci/R&D Officer
—Since 2020-08-31
TI
Terenzio Ignoni→
Chief Tech/Sci/R&D Officer
—Since 2021-05-31
Board of directors7
KI
Khalid Islam→
Chairman
Age 69Since 2016-12-31
JR
Jeffrey Riley→
Director/Board Member
Age 63Since 2019-04-30
DG
Dov Goldstein→
Director/Board Member
Age 58Since 2020-12-31
GM
Gwen Melincoff→
Director/Board Member
Age 74Since 2020-12-31
CN
Claude Nicaise→
Director/Board Member
Age 74Since 2020-12-31
HH
Hans-Peter Hasler→
Director/Board Member
Age 70Since 2021-02-28
GM
Gene Mack→
Director/Board Member
Age 52Since 2025-01-05
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Marshall Wace LLP | 4.149 % | 1,769,788 |
| Potomac Capital Management, Inc. | 2.365 % | 1,008,600 |
| Khalid Islam | 2.182 % | 930,784 |
| The Jones Financial Cos LLLP | 1.481 % | 631,615 |
| Cambridge Investment Research, Inc. | 1.333 % | 568,645 |
Catalog · 2026-07-09
SEC officers12
| Name | Role | Since | Shares |
|---|---|---|---|
| Gene Mack | interim Chief Financial Officer | 2024-06-24 | - |
| Gianluca Fuggetta | Director of Finance/CFO | 2025-01-05 | - |
| Joanne Taylor | Chief Tech/Sci/R&D Officer | 2020-08-31 | - |
| Jonas Hannestad | Chief Tech/Sci/R&D Officer | 2024-03-24 | - |
| Khalid Islam | Chairman | 2016-12-31 | - |
| Terenzio Ignoni | Chief Tech/Sci/R&D Officer | 2021-05-31 | - |
| Claude Nicaise | Director/Board Member | 2020-12-31 | - |
| Dov Goldstein | Director/Board Member | 2020-12-31 | - |
SEC · as of 2026-10-01
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 7.2Range 5–8Analysts 5
5Mean 7.28
- Buy 4
Broker actions40 of 53
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | 8 | 2026-10-05 |
| HC Wainwright & Co. | Reiterated | Buy | 8 | 2026-08-31 |
| BTIG | Reiterated | Buy | 5 | 2026-08-11 |
| HC Wainwright & Co. | Reiterated | Buy | 8 | 2026-07-01 |
| BTIG | Maintained | Buy | 5 | 2026-06-30 |
| HC Wainwright & Co. | Reiterated | Buy | 8 | 2025-12-19 |
| BTIG | Reiterated | Buy | 9 | 2025-10-15 |
| HC Wainwright & Co. | Reiterated | Buy | 8 | 2025-10-13 |
| Maxim Group | Maintained | Buy | 7 | 2025-10-07 |
| BTIG | Reiterated | Buy | 9 | 2025-09-08 |
| Roth Capital | Maintained | Buy | 6 | 2025-08-13 |
| HC Wainwright & Co. | Reiterated | Buy | 8 | 2025-07-03 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.